# Gene Expression in Patients With Metastatic Prostate Cancer Receiving CYP-17 Inhibition Therapy

> **NCT01953640** · — · ACTIVE_NOT_RECRUITING · sponsor: **Mayo Clinic** · enrollment: 92 (actual)

## Conditions studied

- Hormone-Resistant Prostate Cancer
- Metastatic Prostate Carcinoma
- Prostate Adenocarcinoma
- Recurrent Prostate Carcinoma

## Interventions

- **OTHER:** Laboratory Biomarker Analysis
- **OTHER:** Quality-of-Life Assessment

## Key facts

- **NCT ID:** NCT01953640
- **Lead sponsor:** Mayo Clinic
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2013-05-30
- **Primary completion:** 2015-12-03
- **Final completion:** 2026-12-15
- **Target enrollment:** 92 (ACTUAL)
- **Last updated:** 2026-02-03

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01953640

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01953640, "Gene Expression in Patients With Metastatic Prostate Cancer Receiving CYP-17 Inhibition Therapy". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01953640. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*